Selective serotonin reuptake inhibitor pharmacokinetics

Preskorn S. (1997). Clinically relevant pharmacology of selective serotonin reuptake inhibitors. Clinical Pharmacokinetics. 32 1-21. 

Van Harten J Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Chn Pharmacokinet 24 203-230, 1993... 

Baumann P Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996 31(6) 444. [PMID 8968657]... 

Hiemke C. and S. Harther (2000). Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacology and Therapeutics 85 11-28. 

PEDIATRIC PHARMACOKINETIC SELECTIVE SEROTONIN REUPTAKE INHIBITOR STUDIES... 

Wetzel H, Anghelescu 1, Szegedi A, et al Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psy-chopharmacol 18 2-9, 1998... 

Catterson ML, Preskorn SH Pharmacokinetics of selective serotonin reuptake inhibitors Clinical relevance. Pharmacol Toxicol 1996 78(4) 203. [PMID 8861776]... 

Hiemke C, Hartter S Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000 85(1) 11. [PMID 10674711]... 

Catterson, M. O. and Preskom, S. H. Pharmacokinetics of selective serotonin reuptake inhibitors clinical relevance. Pharmacol. Toxicol. 78 (1996) 203-228. 

Lane RM. Pharmacokinetic drug-interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1996 11 31-61. 

Sproule BA, Naranjo CA, Bremner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions-a critical review of the evidence. Clin Pharmacokinet 1997 33 454-471. 

Von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants Relations to pharmacokinetic interactions in vivo. / Clin Psychopharmacol. 1996 16 104-112. 

Psychiatric patients often take multiple psychotropic medications and have medical illnesses that require additional pharmacother-apeutic treatments. Psychiatric practitioners must recognize that administration of multiple medications can alter pharmacokinetic profiles of compounds that are biotransformed by the CYP enzymes. For example, the addition of the popular selective serotonin reuptake inhibitor (SSRI) fluoxetine to a treatment regimen for depression that includes the TCA desipramine has been reported to produce toxic levels of the TCA because of competi-... 

Preskom SH. CUnically relevant pUarmacology of selective serotonin reuptake inhibitors An overview with emphasis on pharmacokinetics and effects on oxidative drug metaboUsm. Qin Pharmacokinet 1997 32(Suppl 1) 1-21. 

Sindrup, S.H., K. Brosen, and L.F. Gram (1992). Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine Nonlinearity and relation to the sparteine oxidation polymorphism, Clin. Pharmacol. Ther. 51, 288-295. 

A. Classification and Pharmacokinetics The major classes of antidepressant drugs are shown in Figure 30-1 tricyclic antidepressants, heterocyclic antidepressants, selective serotonin reuptake inhibitors, and monoamine oxidase inhibitors. 

---